The U.S. Food and Drug Administration (FDA) has recently strengthened warnings about serious mental health side effects associated with montelukast (Singulair and generics), a prescription medication commonly used for asthma and allergy treatment. This action follows an extensive review of available information and the convening of an outside expert panel, leading to the requirement of a Boxed Warning—the most prominent FDA warning—about these potential risks. The updated guidance highlights that serious neuropsychiatric events, including suicidal thoughts or actions, have been reported in patients taking this medication, prompting healthcare providers and patients to carefully consider the risks and benefits of montelukast use.
Background on Montelukast
Montelukast is a prescription medication approved by the FDA in 1998 for the treatment of asthma and allergies. It is marketed under the brand name Singulair and as generic equivalents. The medication works by blocking substances in the body that may cause asthma and allergy symptoms. Montelukast has specific FDA-approved uses including:
- Prevention of asthma attacks
- Long-term treatment of asthma in adults and children 1 year and older
- Prevention of exercise-induced asthma in patients 6 years and older
- Treatment of allergic rhinitis (hay fever)
Despite its long history of use and approval for these conditions, recent safety evaluations have prompted the FDA to reassess the risk-benefit profile of montelukast, particularly for patients with mild allergic rhinitis symptoms.
The FDA's Safety Review and Warning Strengthening
The FDA's decision to strengthen the warnings about montelukast was based on several factors. While prescribing information already included warnings about mental health side effects, including suicidal thoughts or actions, many healthcare professionals and patients were not adequately aware of these risks. The FDA conducted an extensive review of available information, including adverse event reports, observational studies, and animal research.
The Sentinel study, which examined asthma patients aged 6 years and older, along with other observational studies, did not find an increased risk of mental health side effects with montelukast compared to inhaled corticosteroids (ICS). However, the FDA noted that these studies had limitations that may affect how the results should be interpreted. Animal studies showed that montelukast given orally reaches the brain in rats, providing biological plausibility for potential neuropsychiatric effects.
Based on this review, the FDA determined that a Boxed Warning was necessary to highlight the serious mental health risks associated with montelukast. The warning emphasizes that these serious side effects may occur during treatment and in some cases continue after stopping the medication. While many cases resolved after discontinuation of the medicine, this was not universal.
Mental Health Side Effects Associated with Montelukast
The FDA has identified a wide variety of mental health side effects reported with montelukast use. These side effects have occurred in patients with and without a prior history of mental illness. The complete list of reported behavior or mood-related changes includes:
- Agitation, including aggressive behavior or hostility
- Attention problems
- Bad or vivid dreams
- Depression
- Disorientation or confusion
- Feeling anxious
- Hallucinations (seeing or hearing things that are not really there)
- Irritability
- Memory problems
- Obsessive-compulsive symptoms
- Restlessness
- Sleepwalking
- Stuttering
- Suicidal thoughts and actions
- Tremor or shakiness
- Trouble sleeping
- Uncontrolled muscle movements
Notably, these effects have been reported to occur both during montelukast treatment and after stopping the medication. In many cases, symptoms resolved after discontinuing the medicine, but in some instances, the symptoms continued even after stopping treatment. The FDA has also received reports of completed suicides, though the exact relationship to montelukast use remains complex to determine due to various confounding factors.
Patient Considerations and Safety Precautions
Given the serious nature of the reported mental health side effects, the FDA has provided specific guidance for patients and caregivers taking montelukast:
- Patients and parents/caregivers should stop taking montelukast and contact a healthcare professional immediately if behavior or mood-related changes are experienced during treatment.
- The FDA recommends that montelukast should only be used for allergic rhinitis in patients who have an inadequate response to or cannot tolerate alternative therapies.
- For patients with allergies, various steps can be taken to lessen symptoms, including avoiding exposure to allergy triggers, keeping indoor air clean, and taking alternative allergy medications.
The FDA has also mandated a new patient Medication Guide that explains the mental health risks and other important information about montelukast. Patients are encouraged to read this guide every time they receive a prescription for the medication. The guide details potential side effects, the medication's intended uses, proper administration and storage instructions, and other important considerations during treatment.
Additionally, the FDA urges patients and healthcare professionals to report side effects involving montelukast to the FDA MedWatch program. This reporting helps the agency track safety issues with medications and take appropriate regulatory actions.
Alternative Treatments for Asthma and Allergies
Due to the concerns surrounding montelukast's mental health side effects and the availability of alternative treatments, the FDA has reevaluated the risk-benefit profile of the medication. The agency now recommends that montelukast should not be the first-choice treatment for allergic rhinitis, particularly when symptoms are mild, due to the wide availability of other safe and effective allergy medicines with longer histories of safety.
Several alternative treatments are available for patients with asthma and allergies:
Antihistamines
- Loratadine (Alavert, Claritin)
- Fexofenadine (Allegra)
- Cetirizine (Zyrtec)
- Levocetirizine (Xyzal)
- Diphenhydramine (Benadryl)
Steroid Nasal Sprays
- Fluticasone (Flonase)
- Triamcinolone (Nasacort)
- Budesonide (Rhinocort)
Allergen Immunotherapy
Allergen immunotherapy, also known as allergy shots, has been shown to decrease symptoms of allergic rhinitis and may provide long-term relief for allergy sufferers.
A pharmacist or healthcare professional can assist patients in determining which alternative treatment might be most appropriate based on their specific symptoms, medical history, and individual response to different medications.
Healthcare Professional Guidance
The FDA has provided specific recommendations for healthcare professionals regarding montelukast:
- Ask patients about any history of psychiatric illness before initiating montelukast treatment.
- Consider the risks and benefits of montelukast when deciding to prescribe or continue patients on the medication.
- Advise all patients of the risk of neuropsychiatric events when prescribing montelukast.
- Reserve montelukast for allergic rhinitis treatment only in patients who have an inadequate response to or cannot tolerate alternative therapies.
- Consider the severity of the patient's allergic rhinitis symptoms when determining whether montelukast is an appropriate treatment option.
Healthcare professionals are also encouraged to discuss the full range of treatment options with patients, including over-the-counter alternatives that may be effective for mild allergic rhinitis symptoms. This discussion should include the potential risks and benefits of each option, taking into account the patient's individual medical history and symptom severity.
Risk-Benefit Assessment
The FDA's reevaluation of montelukast highlights the importance of careful risk-benefit assessment when prescribing medications. While montelukast may be an effective treatment for some patients, particularly those with moderate to severe asthma or allergic rhinitis that does not respond to other treatments, the potential for serious mental health side effects cannot be overlooked.
The decision to use montelukast should be based on a thorough evaluation of:
- The severity of the patient's asthma or allergy symptoms
- The patient's response to alternative treatments
- The patient's history of mental illness or neuropsychiatric disorders
- The potential risks of untreated asthma or allergies versus the risks of treatment
- The patient's and family's preferences after being fully informed about the risks and benefits
For many patients with mild allergic rhinitis, the FDA now recommends considering alternative treatments first, reserving montelukast for cases where other options have proven ineffective or not tolerated.
Conclusion
The FDA's strengthened warning about mental health side effects associated with montelukast represents an important safety update for healthcare providers and patients. The Boxed Warning and updated Medication Guide will increase awareness of these potential risks, enabling earlier identification and management of neuropsychiatric events.
Patients and healthcare professionals should carefully consider the risks and benefits of montelukast, particularly for the treatment of mild allergic rhinitis where effective alternatives are available. Open communication between patients and healthcare providers about any history of mental illness and any changes in mood or behavior during treatment is essential.
For those currently taking montelukast without experiencing adverse effects, the medication may continue to be an appropriate treatment option for some patients. However, anyone experiencing behavior or mood-related changes should stop taking the medication and contact their healthcare professional immediately.
The FDA's actions underscore the importance of ongoing pharmacovigilance and the need for regular reassessment of medications' risk-benefit profiles as new information becomes available. Patients are encouraged to report any side effects to the FDA MedWatch program, contributing to the broader understanding of medication safety.